All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL HubAML HubGVhD HubLymphoma HubMDS HubMultiple Myeloma Hub

ASH2021: What are the key highlights in MPN?

During the 63rd ASH Annual Meeting and Exposition, the MPN Hub was pleased to speak to Jean-Jacques Kiladjian, Université de Paris and Hôpital Saint-Louis, Paris, FR. We asked, ASH2021: What are the key highlights in MPN?

ASH2021: What are the key highlights in MPN?

In this video, Kiladjian highlights the key advances presented at ASH, particularly in regard to MPN treatment. Kiladjian discusses the JAK2 inhibitor fedratinib and the FREEDOM (NCT03755518) and FREEDOM2 (NCT03952039) trials. He also mentions pelabresib and the MANIFEST (NCT02158858) trial. Lastly, he comments on the lysine-specific histone demethylase-1 (LSD1) inhibitor bomedemstat, CD123-targeting agent tagraxofusp, and AVID200, a transforming growth factor-beta (TGF-beta) inhibitor.

 

Share: